In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ambrx gets $55mm with Series C financing

Executive Summary

Ambrx (optimizes existing protein therapeutics) raised $55mm in a Series C financing led by new investor Apposite. Other first-time backers Glynn Ventures, the Dow Employees' Pension Plan, Scottish Widows Investment, and Union Carbide Employees' Pension Plan were joined by returning shareholders Tavistock Life Sciences, Maverick Capital, 5AM Ventures, Versant Ventures, Aravis Ventures, CMEA Ventures, and Roche Venture Fund. The company will use part of the funds to expand its ReCODE platform for modifying proteins. A member of Apposite has taken a seat on Ambrx's board.
Deal Industry
  • Biotechnology
    • Large Molecule
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies